A 12-week, randomized, double-blind, placebo-group, flexible-dosage study to evaluate the efficacy and safety of Gabitril (tiagabine), at dosages up to 16mg day, in the treatment of chronic post-traumatic stress disorder in adults
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 25 Aug 2006
At a glance
- Drugs Tiagabine (Primary)
- Indications Post-traumatic stress disorders
- Focus Therapeutic Use
- 25 Aug 2006 New trial record.